Vancomycin hydrochloride (Synonyms: 鹽酸萬(wàn)古霉素)

Vancomycin hydrochloride 是用于研究細(xì)菌gan染 (bacterial) 的抗生su。 它通過(guò)抑制易感細(xì)菌的細(xì)胞壁合成的第二階段起作用。 Vancomycin hydrochloride 還改變細(xì)胞膜的滲透性并選擇性地抑制核糖核酸的合成。

生物活性

Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis

IC₅₀ & Target：Bacterial^[1]

體外研究(In Vitro)

Vancomycin is a large glycopeptide compound with a molecular weight of 1450 Da^[1]. Vancomycin is a unique glycopeptide structurally unrelated to any currently available antibiotic. It also has a unique mode of action inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin is active against a large number of species of Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis, Str. agalactiae, Str. bovis, Str. mutans, viridans streptococci, enterococ

體內(nèi)研究(In Vivo)

Vancomycin is administered intravenously, with a standard infusion time of at least 1 h, to minimize infusion-related adverse effects. Subjects with normal creatinine clearance, vancomycin has an α-distribution phase of 30 min to 1 h and a β-elimination half-life of 6-12 h. The volume of distribution is 0.4–1 L/kg. The binding of vancomycin to protein ranges from 10% to 50%. Factors that affect the overall activity of vancomycin include its tissue distribution, inoculum size, and protein-binding effects^[1]. Vancomycin treatment of infected mice is associated with improved clinical, diarrhea, and histopathology scores and survival during treatment^[3].

分子量：1485.71

Formula：C₆₆H₇₆Cl₃N₉O₂₄

CAS 號(hào)：1404-93-9

中文名稱：鹽酸萬(wàn)古霉素

來(lái)源：Streptomyces orientalis

運(yùn)輸條件：Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性數(shù)據(jù)

參考文獻(xiàn)

[1]. Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.

[2]. Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.

[3]. Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96.